Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000902664-25-004966·Cullinan Therapeutics, Inc.
Schedule 13G ownership disclosure
Cullinan Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 230031106
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- LYNX1 CAPITAL MANAGEMENT LP
Shares: 5,766,090.00 · Class: 9.8%
- WESTON NICHOLS
Shares: 5,766,090.00 · Class: 9.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-004966
- Form type
- SCHEDULE 13G/A
- Filer
- Cullinan Therapeutics, Inc.
- CIK
- CIK 1789972
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership